Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor (NYSE: AVTR) delivers essential materials and technologies powering breakthroughs in life sciences and advanced industries. This news hub provides investors and professionals with direct access to official announcements, including product innovations, financial results, and strategic partnerships shaping the future of bioprocessing and semiconductor manufacturing.
Track critical updates across Avantor's core operations: earnings disclosures detailing performance in pharmaceutical solutions, regulatory filings impacting global supply chains, and advancements in sustainable production methods like their viral vector processing systems. Discover how developments in brands like J.T. Baker and Macron Fine Chemicals influence research and manufacturing efficiency worldwide.
Our curated news collection serves as a decision-making tool for monitoring Avantor's role in enabling scientific progress across 180+ countries. Bookmark this page for real-time insights into leadership changes, facility expansions, and emerging applications in gene therapy support systems.
Avantor announced the launch of two new products, J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease, aimed at optimizing the gene therapy harvest process. These products address biopharmaceutical demand for sustainable options while improving the efficiency and quality of viral particle harvests. The J.T.Baker® Cell Lysis Solution, a biodegradable alternative to Octoxynol-9, ensures low ecotoxicity and protects viral particles during processing. It also streamlines the harvest process by reducing contamination risks. In combination with J.T.Baker® Endonuclease, which removes residual impurities, these products offer scalable, efficient, and environmentally friendly solutions for gene therapy manufacturing.
Avantor (NYSE: AVTR), a global provider of vital products and services for the life sciences and advanced technology sectors, announced it will release its Q2 2024 financial results on July 26, 2024, before the market opens. The company will also host a conference call at 8:00 a.m. ET to discuss these results. The live audio webcast can be accessed via the Investor section on Avantor's website, with a replay available for 30 days.
Avantor (NYSE: AVTR) has announced the appointment of Corey Walker as President of its Laboratory Solutions business, effective June 21, 2024. Walker, who has previously held senior roles at Avantor and was most recently CEO of ILC Dover, brings extensive expertise in life sciences and advanced technologies. He will report to CEO Michael Stubblefield. Walker succeeds Randy Stone, who made significant contributions to the Laboratory Solutions segment. Avantor's new operating model, featuring two global segments – Laboratory Solutions and Bioscience Production – became effective in January 2024. The company reaffirms its fiscal year 2024 guidance as previously stated during its Q1 earnings call.
Avantor (NYSE: AVTR) released its 2024 Sustainability Report, detailing significant progress in 2023 across four key pillars: People & Culture, Innovation & Environment, Community Engagement, and Governance & Integrity.
Notably, Avantor met its 2025 greenhouse gas emissions reduction target two years early, achieving a 16.7% decrease from 2019 levels. The company has set new targets for 2030. Avantor earned a top score on the Human Rights Campaign's 2023 Corporate Equality Index and awarded over $1.2 million in grants for healthcare and STEM education. Additionally, Avantor launched a Responsible Supplier Program, enrolling 340 suppliers.
Avantor (NYSE: AVTR), a global provider of mission-critical products in life sciences and advanced technologies, announced that its President and CEO, Michael Stubblefield, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event will take place on June 11, 2024, at 11:20 a.m. Eastern Time in Miami, Fla. A live audio webcast of the session will be available on the Avantor website, and a replay will be accessible for 30 days.
Avantor has announced that its President and CEO, Michael Stubblefield, will participate in a fireside chat at Bernstein's 40th Annual Strategic Decisions Conference. The event will take place in New York on May 30, 2024, at 8:00 a.m. Eastern Time. Attendees can listen to a live audio webcast of the session via the Investor section of Avantor's website. A replay will be accessible for 30 days following the event.
Avantor, Inc. (NYSE: AVTR) will have its President and CEO, Michael Stubblefield, participating in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas on May 14, 2024. Investors can access the live audio webcast on Avantor's website and a replay will be available for 30 days.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
